<?xml version="1.0" encoding="UTF-8"?>
<!-- generated by CLiX/Wiki2XML [MPI-Inf, MMCI@UdS] $LastChangedRevision: 92 $ on 16.04.2009 18:57:08[mciao0828] -->
<!DOCTYPE article SYSTEM "../article.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink">
<header>
<title>Caspofungin</title>
<id>1807310</id>
<revision>
<id>242408599</id>
<timestamp>2008-10-02T03:04:27Z</timestamp>
<contributor>
<username>Thijs!bot</username>
<id>1392310</id>
</contributor>
</revision>
<categories>
<category>Antifungals</category>
</categories>
</header>
<bdy>

<table id="drugInfoBox" style="float: right; clear: right; margin: 0 0 0.5em 1em; background: #ffffff;" width="280" align="right" cellpadding="1" class="toccolours" border="0">

<row>
<col colspan="2" align="center">
 <image width="150px" src="caspofungin.png">
<caption>

 220px 
</caption>
</image>
</col>
</row>
<row>
<col colspan="2" align="center">
Caspofungin</col>
</row>
<row>
<col colspan="2" align="center" bgcolor="#dddddd">
 <b>Systematic (<link xlink:type="simple" xlink:href="../503/3141503.xml">
IUPAC</link>) name</b></col>
</row>
<row>
<col colspan="2" style="text-align: center; vertical-align: top;" bgcolor="#eeeeee">
 1-[(4''R'',5''S'')-5-[(2-aminoethyl)amino]- <it>N</it>2-(10,12-dimethyl-1-oxotetradecyl)- 4-hydroxy-L-ornithine]-5-[(3''R'')- 3-hydroxy-L-ornithine]pneumocandin B0</col>
</row>






<row>
<col colspan="2" bgcolor="#dddddd">
<b>Identifiers</b></col>
</row>
<row>
<col width="90" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../815/160815.xml">
CAS number</link></col>
<col bgcolor="#eeeeee">
 <weblink xlink:type="simple" xlink:href="http://www.nlm.nih.gov/cgi/mesh/2008/MB_cgi?term=179463-17-3&amp;rn=1">
179463-17-3</weblink></col>
</row>
<row>
<col bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../770/2770.xml">
ATC code</link></col>
<col bgcolor="#eeeeee">
 <written_communication wordnetid="106349220" confidence="0.8">
<code wordnetid="106667317" confidence="0.8">
<link>
J02</link></code>
</written_communication>
<weblink xlink:type="simple" xlink:href="http://www.whocc.no/atcddd/indexdatabase/index.php?query=J02AX04">
AX04</weblink></col>
</row>
<row>
<col bgcolor="#ddeeff">
 <institute wordnetid="108407330" confidence="0.8">
<association wordnetid="108049401" confidence="0.8">
<link xlink:type="simple" xlink:href="../723/2863723.xml">
PubChem</link></association>
</institute>
</col>
<col bgcolor="#eeeeee">
 <weblink xlink:type="simple" xlink:href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=468682">
468682</weblink></col>
</row>
<row>
<col bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../731/3408731.xml">
DrugBank</link></col>
<col bgcolor="#eeeeee">
 <weblink xlink:type="simple" xlink:href="http://www.drugbank.ca/cgi-bin/show_drug.cgi?CARD=APRD00199">
APRD00199</weblink></col>
</row>

<row>
<col colspan="2" bgcolor="#dddddd">
<b>Chemical data</b></col>
</row>
<row>
<col bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../043/7043.xml">
Formula</link></col>
<col bgcolor="#eeeeee">
 <link xlink:type="simple" xlink:href="../299/5299.xml">
C</link>52<link xlink:type="simple" xlink:href="../255/13255.xml">
H</link>88<link xlink:type="simple" xlink:href="../175/21175.xml">
N</link>10<link xlink:type="simple" xlink:href="../303/22303.xml">
O</link>15&nbsp;</col>
</row>
<row>
<col bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../836/19836.xml">
Mol. mass</link></col>
<col bgcolor="#eeeeee">
1093.31 g/mol</col>
</row>









<row>
<col colspan="2" bgcolor="#dddddd">
<b>Pharmacokinetic data</b></col>
</row>
<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../021/769021.xml">
Bioavailability</link></col>
<col bgcolor="#eeeeee">
100% (i.v.-use only)</col>
</row>
<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../636/6025636.xml">
Protein binding</link></col>
<col bgcolor="#eeeeee">
97%</col>
</row>
<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../475/1173475.xml">
Metabolism</link></col>
<col bgcolor="#eeeeee">
?</col>
</row>
<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../099/3206099.xml">
Half life</link></col>
<col bgcolor="#eeeeee">
9-11 hours</col>
</row>
<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../468/255468.xml">
Excretion</link></col>
<col bgcolor="#eeeeee">
?</col>
</row>
<row>
<col colspan="2" bgcolor="#dddddd">
<b>Therapeutic considerations</b></col>
</row>
<row>
<col bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../840/1186840.xml">
Licence data</link></col>
<col bgcolor="#eeeeee">
<weblink xlink:type="simple" xlink:href="http://www.emea.europa.eu/humandocs/Humans/EPAR/Cancidas/Cancidas.htm">
EU</weblink>,&nbsp;<weblink xlink:type="simple" xlink:href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&amp;SearchTerm=Caspofungin&amp;SearchType=BasicSearch">
US</weblink></col>
</row>
<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../622/588622.xml">
Pregnancy cat.</link></col>
<col bgcolor="#eeeeee">
C</col>
</row>
<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../840/1186840.xml">
Legal status</link></col>
<col bgcolor="#eeeeee">
℞ Prescription only</col>
</row>

<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <work wordnetid="100575741" confidence="0.8">
<treatment wordnetid="100658082" confidence="0.8">
<event wordnetid="100029378" confidence="0.8">
<care wordnetid="100654885" confidence="0.8">
<act wordnetid="100030358" confidence="0.8">
<psychological_feature wordnetid="100023100" confidence="0.8">
<activity wordnetid="100407535" confidence="0.8">
<link xlink:type="simple" xlink:href="../816/334816.xml">
Routes</link></activity>
</psychological_feature>
</act>
</care>
</event>
</treatment>
</work>
</col>
<col bgcolor="#eeeeee">
 <link xlink:type="simple" xlink:href="../773/178773.xml">
IV</link></col>
</row>
</table>
<p>

<b>Caspofungin</b> (<link xlink:type="simple" xlink:href="../768/611768.xml">
INN</link><ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%221%22])">1</ref>) (brand name Cancidas worldwide) is an <link xlink:type="simple" xlink:href="../172/575172.xml">
antifungal</link> drug, the first of a new class termed the <link xlink:type="simple" xlink:href="../292/9471292.xml">
echinocandin</link>s from <company wordnetid="108058098" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../760/1180760.xml">
Merck &amp; Co., Inc.</link></company>
 It shows activity against infections with <it><fungus wordnetid="112992868" confidence="0.8">
<link xlink:type="simple" xlink:href="../518/1529518.xml">
Aspergillus</link></fungus>
</it> and <it><link xlink:type="simple" xlink:href="../403/758403.xml">
Candida</link></it>, and works by inhibiting the <link xlink:type="simple" xlink:href="../257/9257.xml">
enzyme</link> <link xlink:type="simple" xlink:href="../666/12931666.xml">
β(1,3)-D-Glucan synthase</link> and thereby disturbing the integrity of the fungal <link xlink:type="simple" xlink:href="../312/6312.xml">
cell wall</link>. <b>Caspofungin</b> is administered <link xlink:type="simple" xlink:href="../769/178769.xml">
intravenously</link>.</p>

<sec>
<st>
Indications</st>
<p>

Caspofungin acetate for injection was originally approved by both the <link xlink:type="simple" xlink:href="../632/11632.xml">
FDA</link>, in the US, and the <link xlink:type="simple" xlink:href="../003/629003.xml">
EMEA</link>, in Europe, in 2001. Its currently approved therapeutic indications by both organisms include the empirical therapy of presumed fungal infections in febrile, neutropenic adult patients and the treatment of invasive <link xlink:type="simple" xlink:href="../506/5854506.xml">
aspergillosis</link> in adult patients whose disease is refractory to, or who are intolerant of, other antifungal agents (i.e., conventional or lipid formulations of <link xlink:type="simple" xlink:href="../448/732448.xml">
amphotericin B</link> and/or <link xlink:type="simple" xlink:href="../072/590072.xml">
itraconazole</link>). Additionally, the FDA approval includes indication for the treatment of <link xlink:type="simple" xlink:href="../628/2503628.xml">
candidemia</link> and some specific <it>Candida</it> infections (intra-abdominal abscesses, <link xlink:type="simple" xlink:href="../549/142549.xml">
peritonitis</link>, <link xlink:type="simple" xlink:href="../207/195207.xml">
pleural cavity</link> infections and <link xlink:type="simple" xlink:href="../010/197010.xml">
oesophagitis</link>) and the EMEA approval includes indication for the treatment of general invasive <link xlink:type="simple" xlink:href="../038/7038.xml">
candidiasis</link> in adult patients.</p>

</sec>
<sec>
<st>
Clinical Efficacy</st>
<p>

36% of patients refractory to other therapies responded well to caspofungin therapy, while even 70% of patients intolerant to other therapies were classified as responders. Direct comparative studies to other drugs in the treatment of invasive aspergillosis have so far not been undertaken.</p>

</sec>
<sec>
<st>
Contraindications</st>
<p>

Known hypersensitivity to caspofungin acetate or any other ingredient contained in the formulation</p>

</sec>
<sec>
<st>
Warnings</st>
<p>

<list>
<entry level="1" type="bullet">

 Hepatic Effects</entry>
</list>
</p>
<p>

The concomitant use of caspofungin and cyclosporine in healthy volunteers led to a more frequent increase of liver enzymes (ALT=SGPT and AST=SGOT) than noted with cyclosporine alone. Combination treatment is only indicated, if the potential benefit for the patient outweighs the potential risk.</p>
<p>

Dosage reduction in patients with moderately impaired liver function is recommended. No clinical data exists regarding the use of caspofungin in patients with severely impaired liver function. </p>
<p>

<list>
<entry level="1" type="bullet">

 Sensitivity Reactions</entry>
</list>

Reactions due to histamine release (rash, facial swelling, pruritus, sensation of warmth and one case of anaphylaxis) have been seen. Those reactions should be carefully watched for.</p>
<p>

<list>
<entry level="1" type="bullet">

 Drug Resistance</entry>
</list>

In a few patients with infections caused by C. albicans mutants with reduced sensitivity to caspofungin have been noticed. Currently there is no data regarding development of resistance in other fungi than C. albicans.</p>

</sec>
<sec>
<st>
Pregnancy and lactation</st>
<p>

Caspofungin has in animal studies been shown to have embroyotoxic properties and therefore has been assigned to class C. It should only be given to pregnant women, if the benefit to the mother clearly outweighs the potenial risk to the unborn.</p>
<p>

The drug is found in the milk of lactating rats; it is not known, whether this effect can be seen in women, too. Lactating women should be treated cautiously. </p>

</sec>
<sec>
<st>
Geriatric patients</st>
<p>

Ordinarily, no dose adjustments are necessary.</p>

</sec>
<sec>
<st>
Pediatric patients</st>
<p>

There is no sufficient clinical experience to judge the safety and efficacy in patients younger than 18 years of age.</p>

</sec>
<sec>
<st>
Side-effects</st>
<p>

Compared to amphotericin B, caspofungin seems to have a relatively low incidence of side-effects. In clinical studies and post-marketing reports the side-effects seen in 1% or more of the patients were as follows:</p>
<p>

<list>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../720/69720.xml">
Gastrointestinal system</link> : <link xlink:type="simple" xlink:href="../703/18947703.xml">
nausea</link>, <link xlink:type="simple" xlink:href="../183/8507183.xml">
vomiting</link>, <link xlink:type="simple" xlink:href="../703/593703.xml">
abdominal pain</link>, and <link xlink:type="simple" xlink:href="../951/53951.xml">
diarrhea</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../251/7251.xml">
Central nervous system</link> : <link xlink:type="simple" xlink:href="../893/69893.xml">
headache</link></entry>
<entry level="1" type="bullet">

 Whole body : <link xlink:type="simple" xlink:href="../253/46253.xml">
fever</link>, <link xlink:type="simple" xlink:href="../814/939814.xml">
phlebitis</link> or thrombophlebitis, complications at <link xlink:type="simple" xlink:href="../769/178769.xml">
intravenous cannulation</link> site (e.g. induration), unspecified pain, flu-like-syndrome, myalgia, chills, and <link xlink:type="simple" xlink:href="../940/398940.xml">
paresthesia</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../723/66723.xml">
Respiratory</link> : <link xlink:type="simple" xlink:href="../033/200033.xml">
dyspnea</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../025/17025.xml">
Renal</link> : increased plasma <link xlink:type="simple" xlink:href="../623/65623.xml">
creatinine</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../997/3997.xml">
Hematological</link> : <link xlink:type="simple" xlink:href="../537/83537.xml">
anemia</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../336/48336.xml">
Electrolyte</link>s : <link xlink:type="simple" xlink:href="../656/972656.xml">
hypokalemia</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../301/17384301.xml">
Liver</link> : increased <link xlink:type="simple" xlink:href="../923/211923.xml">
liver enzyme</link>s (asymptomatic)</entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../058/335058.xml">
Hypersensitivity</link> : rash, facial edema, <link xlink:type="simple" xlink:href="../302/424302.xml">
pruritus</link></entry>
<entry level="1" type="bullet">

 Others : <link xlink:type="simple" xlink:href="../581/160581.xml">
tachycardia</link> </entry>
</list>
</p>
<p>

Additionally, infrequent cases of symptomatic liver damage, peripheral edema and swelling, and <link xlink:type="simple" xlink:href="../274/512274.xml">
hypercalcemia</link> have been seen. One case of <link xlink:type="simple" xlink:href="../240/74240.xml">
anaphylaxis</link> (severe allergic reaction) has also been noted.</p>

</sec>
<sec>
<st>
Resistance</st>
<p>

Resistance in <link xlink:type="simple" xlink:href="../673/411673.xml">
Candida albicans</link> has been described but is currently still rare.  The mechanism is probably a point mutation in the 1→3-β-D-glucan synthase gene.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%222%22])">2</ref></p>

</sec>
<sec>
<st>
Drug interactions</st>
<p>

<list>
<entry level="1" type="bullet">

 Cyclosporine : see under Hepatic Effects</entry>
<entry level="1" type="bullet">

 Tacrolimus : potential pharmacokinetic interactions</entry>
<entry level="1" type="bullet">

 Other systemic antimycotic agents : with amphotericin B, itraconazole and mycophenolate no interactions have been seen</entry>
<entry level="1" type="bullet">

 Inducers of drug clearance (e.g. carbamazepine, phenytoin, rifampin, dexamethason) : consider 70mg i.v. as maintenance dose instead of 50mg</entry>
</list>
</p>

</sec>
<sec>
<st>
Duration of treatment</st>
<p>

The mean duration of therapy in previous studies was 34 days. Some patients were even healed by a 1-day treatment. However, a few patients were treated for as long as 162 days and tolerated the drug well, indicating that longtime use may be indicated and tolerated favourably in complicated cases of aspergillosis. Generally, the duration of treatment is dictated by the severity of the disease, the clinical response and the improvement of immunecompetence in immunecompromised patients. </p>

</sec>
<sec>
<st>
Dosage</st>
<p>

An initial dose of 70 mg by i.v.-infusion is given followed by 50 mg i.v. daily. If no response is seen or if inducers of caspofungin clearance (see above) are coadministered the daily dose may be increased to 70 mg i.v. An infusion should take approximately 1 hour.</p>

</sec>
<sec>
<st>
Dosage forms</st>
<p>

<list>
<entry level="1" type="bullet">

 Cancidas 50mg for i.v.-infusion (manufacturer Merck)</entry>
<entry level="1" type="bullet">

 Cancidas 70mg for i.v.-infusion (manufacturer Merck)</entry>
<entry level="1" type="bullet">

 Brand names in countries other than the US may vary.   </entry>
</list>
</p>

</sec>
<sec>
<st>
External references</st>
<p>

<list>
<entry level="1" type="bullet">

 AHFS Database</entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.cdc.gov/ncidod/dbmd/diseaseinfo/aspergillosis_t.htm">
CDC on Aspergillosis</weblink></entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.kompendium.ch/MonographieTxt.aspx?lang=de&amp;MonType=fi">
Swiss pharma-compendium on Caspofungin</weblink></entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.cancidas.com/cancidas/shared/documents/english/pi.pdf">
Cancidas.com</weblink></entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.fda.gov/cder/foi/label/2005/21227s015lbl.pdf">
FDA on Cancidas</weblink></entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.emea.europa.eu/humandocs/PDFs/EPAR/cancidas/H-379-PI-en.pdf">
EMEA on Cancidas</weblink></entry>
</list>
</p>

<p>

<table style=";" class="navbox" cellspacing="0">
<row>
<col style="padding:2px;">
<table style="width:100%;background:transparent;color:inherit;;" class="nowraplinks collapsible autocollapse " cellspacing="0">
<row>
<header colspan="2" style=";" class="navbox-title">
<link xlink:type="simple" xlink:href="../172/575172.xml">
Antifungals</link> (<written_communication wordnetid="106349220" confidence="0.8">
<code wordnetid="106667317" confidence="0.8">
<link>
D01</link></code>
</written_communication>
 and <written_communication wordnetid="106349220" confidence="0.8">
<code wordnetid="106667317" confidence="0.8">
<link>
J02</link></code>
</written_communication>
)</header>
</row>
<row style="height:2px;">

</row>
<row>
<col style=";background:PowderBlue;;" class="navbox-group">
<link xlink:type="simple" xlink:href="../910/842910.xml">
Ergosterol</link>inhibitors</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<table style="width:100%;;;;" class="nowraplinks  navbox-subgroup" cellspacing="0">
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: PowderBlue;" class="navbox-group">
<link xlink:type="simple" xlink:href="../019/1855019.xml">
Azole</link>s(<link xlink:type="simple" xlink:href="../045/10906045.xml">
CYP51A1</link>inhibitors)</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
topical: <it><link xlink:type="simple" xlink:href="../286/1117286.xml">
imidazole</link>s</it> (<link xlink:type="simple" xlink:href="../135/12932135.xml">
Bifonazole</link>, <link xlink:type="simple" xlink:href="../187/12932187.xml">
Clomidazole</link>, <link xlink:type="simple" xlink:href="../015/15690015.xml">
Clotrimazole</link>, <link xlink:type="simple" xlink:href="../224/18251224.xml">
Croconazole</link>, <link xlink:type="simple" xlink:href="../380/4850380.xml">
Econazole</link>, <link xlink:type="simple" xlink:href="../120/12932120.xml">
Fenticonazole</link>, <link xlink:type="simple" xlink:href="../661/781661.xml">
Ketoconazole</link>, <link xlink:type="simple" xlink:href="../171/12932171.xml">
Isoconazole</link>, <link xlink:type="simple" xlink:href="../403/906403.xml">
Miconazole</link>, <link xlink:type="simple" xlink:href="../916/17702916.xml">
Neticonazole</link>, <link xlink:type="simple" xlink:href="../053/4569053.xml">
Oxiconazole</link>, <link xlink:type="simple" xlink:href="../583/5033583.xml">
Sertaconazole</link>, <link xlink:type="simple" xlink:href="../448/5127448.xml">
Sulconazole</link>, <link xlink:type="simple" xlink:href="../397/3114397.xml">
Tioconazole</link>) • <it><link xlink:type="simple" xlink:href="../919/3046919.xml">
triazole</link>s</it> (<link xlink:type="simple" xlink:href="../867/816867.xml">
Fluconazole</link>, <link xlink:type="simple" xlink:href="../601/8294601.xml">
Fosfluconazole</link>) • <it><link xlink:type="simple" xlink:href="../077/1387077.xml">
benzimidazole</link></it> (<link xlink:type="simple" xlink:href="../957/2196957.xml">
Thiabendazole</link>)systemic: <it><link xlink:type="simple" xlink:href="../919/3046919.xml">
triazole</link>s</it> (<link xlink:type="simple" xlink:href="../072/590072.xml">
Itraconazole</link>, <link xlink:type="simple" xlink:href="../069/5347069.xml">
Posaconazole</link>, <link xlink:type="simple" xlink:href="../869/2452869.xml">
Voriconazole</link>)</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: PowderBlue;" class="navbox-group">
<link xlink:type="simple" xlink:href="../498/2550498.xml">
Polyene antimycotic</link>s(<link xlink:type="simple" xlink:href="../910/842910.xml">
ergosterol</link>binding)</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
topical: (<link xlink:type="simple" xlink:href="../956/1115956.xml">
Natamycin</link>, <link xlink:type="simple" xlink:href="../444/732444.xml">
Nystatin</link>)systemic: (<physical_entity wordnetid="100001930" confidence="0.8">
<substance wordnetid="100020090" confidence="0.8">
<causal_agent wordnetid="100007347" confidence="0.8">
<antibiotic wordnetid="102716866" confidence="0.8">
<antibacterial wordnetid="102716205" confidence="0.8">
<medicine wordnetid="103740161" confidence="0.8">
<agent wordnetid="114778436" confidence="0.8">
<drug wordnetid="103247620" confidence="0.8">
<link xlink:type="simple" xlink:href="../448/732448.xml">
Amphotericin B</link></drug>
</agent>
</medicine>
</antibacterial>
</antibiotic>
</causal_agent>
</substance>
</physical_entity>
)</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: PowderBlue;" class="navbox-group">
<link xlink:type="simple" xlink:href="../958/5120958.xml">
Allylamine</link>s(<link xlink:type="simple" xlink:href="../892/10905892.xml">
squalene monooxygenase</link>inhibitors)</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
topical: (<link xlink:type="simple" xlink:href="../843/11569843.xml">
Amorolfine</link>, <link xlink:type="simple" xlink:href="../586/6624586.xml">
Butenafine</link>, <link xlink:type="simple" xlink:href="../964/12931964.xml">
Naftifine</link>, <link xlink:type="simple" xlink:href="../741/1130741.xml">
Terbinafine</link>)systemic: (<link xlink:type="simple" xlink:href="../741/1130741.xml">
Terbinafine</link>)</col>
</row>
</table>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";background:PowderBlue;;" class="navbox-group">
<link xlink:type="simple" xlink:href="../666/12931666.xml">
1,3-beta-glucan synthase</link>inhibitors</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<it><link xlink:type="simple" xlink:href="../292/9471292.xml">
echinocandin</link>s</it> (<link xlink:type="simple" xlink:href="../237/3125237.xml">
Anidulafungin</link>, <link xlink:type="simple" xlink:href="../310/1807310.xml">
Caspofungin</link>, <link xlink:type="simple" xlink:href="../828/12931828.xml">
Micafungin</link>)</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";background:PowderBlue;;" class="navbox-group">
Intracellular</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<table style="width:100%;;;;" class="nowraplinks  navbox-subgroup" cellspacing="0">
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: PowderBlue;" class="navbox-group">
<link xlink:type="simple" xlink:href="../569/17911569.xml">
Pyrimidine analogue</link>s/<link xlink:type="simple" xlink:href="../325/9933325.xml">
Thymidylate synthase</link>inhibitors</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../767/3368767.xml">
Flucytosine</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: PowderBlue;" class="navbox-group">
<work wordnetid="100575741" confidence="0.8">
<treatment wordnetid="100658082" confidence="0.8">
<event wordnetid="100029378" confidence="0.8">
<care wordnetid="100654885" confidence="0.8">
<act wordnetid="100030358" confidence="0.8">
<psychological_feature wordnetid="100023100" confidence="0.8">
<activity wordnetid="100407535" confidence="0.8">
<link xlink:type="simple" xlink:href="../588/12203588.xml">
Mitotic inhibitor</link></activity>
</psychological_feature>
</act>
</care>
</event>
</treatment>
</work>
s</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<link xlink:type="simple" xlink:href="../204/1067204.xml">
Griseofulvin</link></col>
</row>
</table>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";background:PowderBlue;;" class="navbox-group">
Others</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<link xlink:type="simple" xlink:href="../110/1857110.xml">
Ciclopirox</link> • <link xlink:type="simple" xlink:href="../743/1730743.xml">
Ethylparaben</link> • <link xlink:type="simple" xlink:href="../143/28143.xml">
Salicylic acid</link> • <link xlink:type="simple" xlink:href="../327/2311327.xml">
Selenium sulfide</link> • <link xlink:type="simple" xlink:href="../364/1088364.xml">
Tolnaftate</link> • <link xlink:type="simple" xlink:href="../769/8652769.xml">
Undecylenic acid</link><link xlink:type="simple" xlink:href="../966/646966.xml">
Tea tree oil</link> • <link xlink:type="simple" xlink:href="../699/948699.xml">
citronella oil</link> • <link xlink:type="simple" xlink:href="../883/194883.xml">
lemon grass</link> • <link xlink:type="simple" xlink:href="../960/2978960.xml">
orange oil</link> • <link xlink:type="simple" xlink:href="../532/299532.xml">
patchouli</link> • <link xlink:type="simple" xlink:href="../678/2940678.xml">
lemon myrtle</link> • <link xlink:type="simple" xlink:href="../165/17529165.xml">
Whitfield's ointment</link></col>
</row>
</table>
</col>
</row>
</table>
</p>


</sec>
<sec>
<st>
References</st>

<p>

<reflist>
<entry id="1">
<weblink xlink:type="simple" xlink:href="http://www.emea.europa.eu/htms/human/epar/c.htm">
European Medicines Agency's list of authorised medicines for human use (C)</weblink></entry>
<entry id="2">
 <cite style="font-style:normal">Baixench M, Aoun N, Desnos-Ollivier M, et al.&#32;(2007).&#32;"Acquired resistance to echinocandins in Candida albicans: case report
and review". <it>Journal of Antimicrobial Chemotherapy</it>&#32;<b>59</b>&#32;(6): 1076&ndash;1083. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1093%2Fjac%2Fdkm095">
10.1093/jac/dkm095</weblink>. PMID 17468115.</cite>&nbsp;</entry>
</reflist>
</p>


</sec>
</bdy>
</article>
